A
Ability Pharmaceuticals — Series A (estimated) · €3.5M
€3.5M from Inveready Biotech III, the everis Group's corporate venture fund FiTalent, and Capital Cell investors. The money was to finish the phase 2 trial of ABTL0812 in endometrial and lung cancer and to license the drug to a pharma partner. Inveready and FiTalent each took a board seat.
Lead unknown
RoundSeries A (estimated)
Announced12 Sep 2019
CityCerdanyola del Vallès
SectorHealthtech & Bio · Biotech / Oncology
Source
A
